Prostate Cancer Recurrent Clinical Trials

11 recruitingLast updated: June 17, 2026

There are 11 actively recruiting prostate cancer recurrent clinical trials across 9 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Albuquerque, New Mexico, United States, Augsburg, Bavaria, Germany, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Prostate Cancer Recurrent Trials at a Glance

11 actively recruiting trials for prostate cancer recurrent are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Albuquerque, Augsburg, and Beijing. Lead sponsors running prostate cancer recurrent studies include Clarity Pharmaceuticals Ltd, Essen Biotech, and Azienda Ospedaliero-Universitaria Careggi.

Browse prostate cancer recurrent trials by phase

Treatments under study

About Prostate Cancer Recurrent Clinical Trials

Looking for clinical trials for Prostate Cancer Recurrent? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostate Cancer Recurrent trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostate Cancer Recurrent clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Not Applicable

Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era

Prostate CancerProstate Cancer Recurrent
University Health Network, Toronto20 enrolled1 locationNCT06508567
Recruiting
Phase 1Phase 2

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

Solid Tumor, AdultProstate Cancer Recurrent
Medical University of South Carolina76 enrolled1 locationNCT05036226
Recruiting

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

Prostate CancerAdvanced Prostate CancerProstate Cancer Metastatic Disease+1 more
Maastricht Radiation Oncology600 enrolled3 locationsNCT07004582
Recruiting
Phase 3

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Prostate CancerCryotherapyProstate Cancer Recurrent+3 more
Clarity Pharmaceuticals Ltd220 enrolled28 locationsNCT06970847
Recruiting
Phase 2

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Prostate CancerProstate CarcinomaProstate Neoplasm+15 more
Shehzad Basaria, M.D.60 enrolled1 locationNCT06957691
Recruiting
Phase 1Phase 2

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting

Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy

Prostate Cancer RecurrentProstate Cancer (Diagnosis)Prostate Cancer Patients Treated by Radiotherapy+1 more
University of Erlangen-Nürnberg Medical School200 enrolled3 locationsNCT07131956
Recruiting
Phase 3

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Prostate CancerMetastatic CancerProstate Cancer Metastatic+4 more
Universitaire Ziekenhuizen KU Leuven873 enrolled1 locationNCT05352178
Recruiting
Phase 1

Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer

Prostate Cancer Recurrent
University Hospital Tuebingen56 enrolled1 locationNCT05646550
Recruiting
Phase 2

PSMA-RLT in Biochemically Recurrent PCa

Prostate Cancer Recurrent
Medical University of Vienna20 enrolled1 locationNCT06220188
Recruiting

PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE

Prostate CancerProstate AdenocarcinomaProstate Cancer Recurrent+1 more
Azienda Ospedaliero-Universitaria Careggi180 enrolled1 locationNCT05022914